This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Walgreens Boots Alliance (WBA) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $11.23, moving +1.72% from the previous trading session.
CVS Health Post-Q4 Earnings: Is the Stock Worth Buying Now?
by Urmimala Biswas
CVS Health's adjusted EPS outlook for 2025 reflects expectations of a meaningful recovery in Medicare Advantage and continued growth in Health Services.
Moody's Downgrades WBA's Outlook: Should You Hold or Sell the Stock?
by Moumi Mondal
Despite Moody's latest negative rating, Walgreens' focus on operational turnaround and improving cash flows makes it a good hold.
Walgreens Boots Alliance (WBA) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $9.70, moving -0.51% from the previous trading session.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Zacks Earnings Trends Highlights: Coca-Cola, CVS, Pepsi and Walgreens Boots Alliance
by Zacks Equity Research
Coca-Cola, CVS, Pepsi and Walgreens Boots Alliance have been highlighted in this Earnings Trends article.
Breaking Down the Current Earnings Outlook
by Sheraz Mian
We can safely say that it has been a good reporting cycle, with the growth pace showing a notable accelerating trend and companies comfortably beating consensus estimates. But what about the coming periods?
Breaking Down the Current Earnings Outlook
by Sheraz Mian
We can safely say that it has been a good reporting cycle, with the growth pace showing a notable accelerating trend and companies comfortably beating consensus estimates. But what about the coming periods?
These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Walgreens Boots Alliance (WBA) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $10.12, indicating a +0.7% shift from the previous trading day.
Walgreens Boots Alliance (WBA) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Walgreens Boots Alliance (WBA) settling at $9.89, representing a +1.33% change from its previous close.
CVS Health's Pre-Q4 Earnings: Time to Buy, Hold or Sell the Stock?
by Urmimala Biswas
Given that CVS Health's restructuring plan is described as enterprise-wide and ongoing, it is reasonable to expect significant charges in the fourth quarter.
Company News for Jan 22, 2025
by Zacks Equity Research
Companies In The Article Are:MRNA, WBA, FITB and PLD
Company News for Jan 13, 2025
by Zacks Equity Research
Companies in The News Are: DAL, WBA, STZ and TLRY
WBA Q1 Earnings and Revenues Beat Estimates, Stock Up in Pre-Market
by Zacks Equity Research
Walgreens delivers better-than-expected earnings and revenues in the first quarter of fiscal 2025.
Walgreens (WBA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Walgreens (WBA) give a sense of how its business performed in the quarter ended November 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Walgreens Boots Alliance (WBA) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 37.84% and 6.41%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Walgreens Stock Be in Your Portfolio Before Q1 Earnings?
by Moumi Mondal
WBA's fiscal 2025 first-quarter results are expected to continue to reflect a soft U.S. Retail Pharmacy performance.
CVS Stock Trades Near 52-Week Low: Should You Buy the Dip?
by Urmimala Biswas
CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the resumption of member redeterminations.
Exploring Analyst Estimates for Walgreens (WBA) Q1 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Walgreens (WBA) for the quarter ended November 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Alpine Income's 2024 Investment Activity Reaches $134.7 Million
by Zacks Equity Research
PINE's Lowe's acquisition and smart dispositions set the stage for stable income and long-term growth in 2025 and beyond.
Analysts Estimate Walgreens Boots Alliance (WBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Walgreens Boots Alliance (WBA) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Walgreens Boots Alliance (WBA) concluded the recent trading session at $9.33, signifying a +0.76% move from its prior day's close.
Alpine Income Stock Down 7.8% in 3 Months: Should You Buy the Dip?
by Moumita C. Chattopadhyay
Despite the recent sell-off amid the Fed's hawkish stance, PINE's dividend yield, robust portfolio and strategic growth invite to assess if the current level offers a good entry point.
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Walgreens Boots Alliance (WBA) settling at $9.19, representing a -1.18% change from its previous close.